Advent Therapeutics Overview
- Founded
- 2014
- Status
- Private
- Latest Deal Type
- Grant
- Latest Deal Amount
- $225K
- Investors
- 2
Advent Therapeutics General Information
Description
Developer of therapies designed for micro-orphan applications. The company develops a prenatal, neonatal and pediatric drug for orphans to cure disorder in newborn infants in the intensive care unit (ICU), enabling pediatricians and healthcare professionals to care for the fragile in an advanced manner.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 6500 Old Carversville Road
- Lumberville, PA 18933
- United States
Advent Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 01-Jan-2018 | $225K | 00000 | Completed | Product Development | |
| 3. Early Stage VC | 12-Sep-2016 | 00000 | 00000 | Completed | Product Development | |
| 2. Seed Round | 19-Aug-2015 | $120K | $120K | Completed | Product Development | |
| 1. Seed Round | 11-Dec-2014 | Completed | Product Development |
Advent Therapeutics Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Thomas Hofmann Ph.D | Chief Scientific Advisor | ||
| David Lopez JD | Co-Founder, Chief Financial Officer, Chief Business Officer & President |
Advent Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| Ben Franklin Technology Partner of Southeastern Pennsylvania | Venture Capital | Minority | 000 0000 | 000000 0 |